Ascendis Pharma A/S
ASND
$164.65
-$4.19-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -410.04M | -462.57M | -530.08M | -544.53M | -521.22M |
| Total Depreciation and Amortization | 18.66M | 19.23M | 19.58M | 19.92M | 19.93M |
| Total Amortization of Deferred Charges | 497.80K | 520.00K | 520.00K | 520.00K | 520.00K |
| Total Other Non-Cash Items | 172.79M | 180.52M | 275.41M | 209.62M | 102.79M |
| Change in Net Operating Assets | -112.81M | -21.39M | -123.17M | -143.95M | -107.86M |
| Cash from Operations | -330.90M | -283.70M | -357.73M | -458.42M | -505.84M |
| Capital Expenditure | -1.54M | -1.03M | -1.58M | -1.69M | -2.64M |
| Sale of Property, Plant, and Equipment | 1.02M | 1.03M | 1.08M | 55.50K | 55.50K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.98M | 15.03M | 40.27M | 91.86M | 310.94M |
| Cash from Investing | 7.46M | 15.03M | 39.77M | 90.22M | 308.36M |
| Total Debt Issued | 134.16M | 130.63M | 136.26M | 136.26M | 136.26M |
| Total Debt Repaid | -11.37M | -11.15M | -10.96M | -10.66M | -10.44M |
| Issuance of Common Stock | 340.43M | 320.12M | 29.79M | 29.63M | 10.29M |
| Repurchase of Common Stock | -- | -1.81M | -1.81M | -1.81M | -1.81M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -19.29M | -- | -- | -- | -- |
| Cash from Financing | 487.84M | 481.23M | 166.87M | 167.00M | 146.25M |
| Foreign Exchange rate Adjustments | 24.22M | -6.48M | 5.11M | 4.93M | -6.35M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 188.63M | 206.09M | -145.98M | -196.27M | -57.59M |
